Abbisko Therapeutics Strikes Licensing Deal with Merck KGaA for CSF-1R Inhibitor Pimicotinib
Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology company, has announced a licensing agreement...
Boehringer Ingelheim Partners with Shanghai Handu Pharma to Enhance Oral Medication Delivery
Boehringer Ingelheim (BI), a German pharmaceutical company, has entered into a partnership with Shanghai Handu...
Gedeon Richter Acquires Rights to Mithra’s Contraceptive and Menopause Treatments for Chinese Market
Gedeon Richter Plc, a Hungarian pharmaceutical company, and Belgium’s Mithra (OTCMKTS: MITPF) have entered into...
Aspen Pharmacare Holdings to Boost China Presence with Full Acquisition of Sandoz’s Subsidiary
Aspen Pharmacare Holdings (JSE: APN), a South Africa-based pharmaceutical company, is poised to enhance its...
AstraZeneca Halts Late-Stage Trials for Lokelma in Hyperkalemia Due to Timing and Event Rate Issues
AstraZeneca (AZ; NASDAQ: AZN), a leading UK pharmaceutical company, has announced the termination of two...
Roche Expands Beyond Oncology with USD 2.7 Billion Carmot Therapeutics Acquisition
Swiss pharmaceutical giant Roche (SWX: ROG) has entered into an agreement to acquire U.S. biotech...
Stem-Cell Startup Xellsmart Earns FDA Orphan Drug Designation for ALS Therapy
Xellsmart, a stem-cell startup headquartered in Suzhou, has announced that it has received orphan drug...
Worg Pharmaceuticals Gets FDA Approval for Phase II Graves’ Disease Study
Worg Pharmaceuticals, a Hangzhou-based developer of allergic drugs, has received the green light from the...
Nanchang Baiji Pharmaceutical’s Budesonide Nasal Spray Approved by China’s NMPA
Nanchang Baiji Pharmaceutical Co. Ltd., a Chinese pharmaceutical company, has received approval from the National...
Eli Lilly’s Jaypirca Receives FDA Accelerated Approval for Chronic Lymphocytic Leukemia
The US Food and Drug Administration (FDA) has granted Eli Lilly (NYSE: LLY) an accelerated...
Autobio Diagnostics and China National Medical Device Form Strategic Partnership
Autobio Diagnostics Co., Ltd (SHA: 603658), a Chinese in-vitro diagnostics company, has entered into a...
Valgen Secures NMPA Approval for China’s First Transcatheter Mitral Valve Clamp System
Hangzhou-based Valgen Holding Corporation has received market approval from the National Medical Products Administration (NMPA)...
Ambio Gains FDA Approval for Generic Forteo, Challenging Eli Lilly’s Osteoporosis Market
Ambio has secured regulatory approval from the U.S. Food and Drug Administration (FDA) for its...
Chinese Firms Secure EUAs for Omicron XBB Vaccines Amid Dominant Variant Surge
A wave of Chinese pharmaceutical companies has announced the receipt of Emergency Use Authorizations (EUAs)...
Pfizer’s Danuglipron Phase IIb Trial Achieves Weight Loss Goals Amid Tolerability Concerns
Pfizer (NYSE: PFE) announced last week that its Phase IIb trial evaluating danuglipron, a glucagon-like...
Everest Medicines Secures IND Review for Zetomipzomib in China
Everest Medicines (HKG: 1952) has announced that its Investigational New Drug (IND) application for zetomipzomib...
Sunshine Guojian’s SSGJ-608 Meets Phase III Efficacy Endpoints in Psoriasis Trial
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., a subsidiary of 3SBio Inc. (HKG: 1530), has announced...
Novartis Invests USD 86.4 Million in New Radiotherapy Facility in China
Swiss pharmaceutical giant Novartis (NYSE: NVS) has invested over 600 million Chinese yuan (approximately USD...
AbbVie to Acquire ImmunoGen for USD 10.1 Billion, Expanding Oncology Portfolio
AbbVie (NYSE: ABBV) has reached an agreement to acquire fellow U.S. biotech ImmunoGen (NASDAQ: IMGN)...
Akeso Biopharma Files New Indication for Penpulimab in First-Line NPC Treatment
Akeso Biopharma (HKG: 9926) has announced a new indication filing for its programmed death-1 (PD-1)...